Ironwood Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 267
- Market Cap
- $782.7M
- Introduction
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT05740007
- Locations
- 🇺🇸
Urology Associates of Mobile, Mobile, Alabama, United States
🇺🇸Velocity Clinical Research, Mobile, Alabama, United States
🇺🇸Ironwood Research Center, Charleston, South Carolina, United States
A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05362695
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05188261
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 515
- Registration Number
- NCT03931785
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Barrett Clinic, P.C. - BTC - PPDS, La Vista, Nebraska, United States
🇺🇸New Phase Research & Development, Knoxville, Tennessee, United States
Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT03856970
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 614
- Registration Number
- NCT03573908
- Locations
- 🇺🇸
Long Island Gastrointestinal Research Group, LLP, Great Neck, New York, United States
🇺🇸Meritus Center For Clinical Research, Hagerstown, Maryland, United States
🇺🇸Boston Clinical Trials, Inc., Boston, Massachusetts, United States
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
- Conditions
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 495
- Registration Number
- NCT03561090
- Locations
- 🇺🇸
Advanced Research Institute, Ogden, Utah, United States
🇺🇸Medication Management LLC, Greensboro, North Carolina, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
- Conditions
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 609
- Registration Number
- NCT03561883
- Locations
- 🇺🇸
Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States
🇺🇸Carolina Digestive Diseases, Greenville, North Carolina, United States
🇺🇸Morristown Medical Center, Morristown, New Jersey, United States
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03226899
- Locations
- 🇺🇸
Four Rivers Clinical Research, Paducah, Kentucky, United States
🇺🇸Southern Arizona VA Health Care System, Tucson, Arizona, United States
🇭🇺Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo, Békéscsaba, Hungary
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
- Conditions
- Interventions
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02837783
- Locations
- 🇬🇧
Peter Whorwell, Wythenshawe, Manchester, United Kingdom